Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 6/20 | 0.75 |
| ▸ | CASP2 | P42575 | 1/20 | 0.58 |
| ▸ | NAAA | Q02083 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 2/20 | 0.54 |
| ▸ | MGLL | Q99685 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17850647 | 0.92 | EPHX1 (0.62) | EPHX1CASP2NAAAFAAHMEN1 | |
| SCHEMBL13387508 | 0.86 | EPHX1 (1.00) | EPHX1CASP2MGLL | |
| SCHEMBL28556990 | 0.86 | EPHX1 (1.00) | EPHX1CASP2MGLL | |
| SCHEMBL10118264 | 0.86 | EPHX1 (1.00) | EPHX1CASP2MGLL | |
| SCHEMBL717504 | 0.86 | EPHX1 (1.00) | EPHX1CASP2MGLL | |
| SCHEMBL3910901 | 0.86 | EPHX1 (1.00) | EPHX1CASP2MGLL | |
| SCHEMBL1616893 | 0.86 | EPHX1 (1.00) | EPHX1CASP2MGLL | |
| SCHEMBL13387440 | 0.86 | EPHX1 (1.00) | EPHX1CASP2MGLL | |
| SCHEMBL22693961 | 0.86 | EPHX1 (1.00) | EPHX1CASP2MGLL | |
| SCHEMBL27052567 | 0.86 | EPHX1 (1.00) | EPHX1CASP2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2714036-B1 | SUBSITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS | ACHILLION PHARMACEUTICALS INC (US) | 2016-06-22 | — | — | EP | disclosed |